Add to Calendar 2025/11/08 12:30:00 2025/11/08 13:30:00 America/New_York LEGION-100 Phase 2 Trial Enrolling: 3rd Generation Immunotherapy for mCRPC Patients Description: Leading investigators and clinical innovators will provide in-depth insights into SYNC-T SV-102, a novel third-generation combination intratumoral/locoregional immunotherapy designed to elicit a systemic antitumor response in patients with metastatic castration-resistant prostate cancer (mCRPC).
This session will showcase Phase 1 clinical results demonstrating safety, immune activation, and early signs of efficacy, highlighting how SYNC-T SV-102 is reshaping the therapeutic landscape for advanced prostate cancer.
Largely, the symposium will spotlight the LEGION-100 Phase 2 clinical trial, now actively enrolling patients and recruiting clinical trial sites across the U.S. Investigators will share insights into the trial’s design, scientific rationale, and the opportunity for institutions to partner in evaluating this cutting-edge immunotherapy.
Speakers: Charles J. Link, MD (Adjunct Professor, Lankenau Institute for Medical Research & Executive Chairman, Syncromune), Leonard J. Appleman, MD, PhD (Associate Professor of Medicine, University of Pittsburgh, Division of Hematology/Oncology), and George C. Prendergast, PhD (President & CEO, Lankenau Institute for Medical Research, Main Line Health). Chesapeake JKL Room @ Gaylord National Resort & Convention Center, 201 Waterfront St., Oxon Hill, MD 20745 false MM/DD/YYYY 30 OPAQUE aPGZvUIgLzYpmrFACmKE326542